In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Aytu BioScience (AYTU – Research Report), with a price target of $9.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors including the acquisition of a transformative asset, EXXUA, by Aytu BioPharma. This acquisition is expected to significantly enhance the company’s portfolio, particularly with the anticipated launch of EXXUA in the fourth quarter of 2025 aimed at addressing major depressive disorder (MDD).
Naz Rahman also updated the company’s estimates and raised the 12-month price target to $9, reflecting a positive outlook on the stock’s potential growth. The strategic move to acquire EXXUA positions Aytu BioPharma to capitalize on new market opportunities, thereby justifying the Buy rating.
Rahman covers the Healthcare sector, focusing on stocks such as Palisade Bio, Galmed Pharmaceuticals, and Vivani Medical. According to TipRanks, Rahman has an average return of -19.8% and a 26.76% success rate on recommended stocks.